Back to top
more

PTC Therapeutics (PTCT)

(Real Time Quote from BATS)

$40.15 USD

40.15
536,454

-2.23 (-5.26%)

Updated Nov 15, 2024 01:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

PTC Therapeutics (PTCT) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Earnings Preview: ImmunoGen (IMGN) Q1 Earnings Expected to Decline

by Zacks Equity Research

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug

by Zacks Equity Research

Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -19.90% and 6.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 8.55% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why PTC Therapeutics (PTCT) is Poised for a Turnaround After Losing 23.4% in 4 Weeks

by Zacks Equity Research

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -11.68% and 11.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US

by Zacks Equity Research

The FDA requests additional data to allow PTC Therapeutics (PTCT) to continue enrollment in its phase II PIVOT-HD study evaluating PTC518 for treating Huntington's disease in the United States. Stock down.

PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -27.54% and 13.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche's (RHHBY) Evrysdi Gets FDA Nod for Label Extension

by Zacks Equity Research

The FDA approves a label expansion of Roche's (RHHBY) SMA drug Evrysdi to include less than two-month old babies with SMA.

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -14.84% and 2.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) Soars 11.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

United Therapeutics (UTHR) Moves 3.1% Higher: Will This Strength Last?

by Zacks Equity Research

United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for PTC Therapeutics (PTCT) This Earnings Season?

by Zacks Equity Research

PTC Therapeutics (PTCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in PTC Therapeutics (PTCT): Can Its 5.1% Jump Turn into More Strength?

by Zacks Equity Research

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.